DOI: 10.36347/sjams.2018.v06i12.054

Pages: 4927-4934

Despite overwhelming data supporting the use of ticagrelor as an alternate potent antiplatelet agent in percutaneous intervention (PCI) with drug eluting stent (DES), to the best of our knowledge there is no study which assessed safety and efficacy of ticagrelor in PCI with bare metal stent (BMS). We aimed to study ticagrelor in cases of PCI with BMS in terms of primary (major adverse cardiac events composite of myocardial infarction, unplanned revascularization and stroke) and secondary (in-stent restenosis, re-hospitalisation, minor bleed and drug switch) end points. This is a prospective, single center, open label observational study conducted between Feb 2016 to July 2016 at post graduate department of cardiology JLN medical college, Ajmer in patients undergoing primary or elective PCI .Total 276 patients were included in the study.